BRPI0418079A - composto, composição farmacêutica, e, usos de uma composição e de um composto - Google Patents
composto, composição farmacêutica, e, usos de uma composição e de um compostoInfo
- Publication number
- BRPI0418079A BRPI0418079A BRPI0418079-8A BRPI0418079A BRPI0418079A BR PI0418079 A BRPI0418079 A BR PI0418079A BR PI0418079 A BRPI0418079 A BR PI0418079A BR PI0418079 A BRPI0418079 A BR PI0418079A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compound
- treatment
- disorders
- usable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USOS DE UMA COMPOSIçãO E DE UM COMPOSTO". Novos compostos de fórmula estrutural são descritos. Como moduladores do receptor de canabinóide 1 (CB1), estes compostos são utilizáveis no tratamento, prevenção, e supressão de doenças mediadas pelo receptor de CB1. Como tal, os compostos da presente invenção são utilizáveis como no tratamento, prevenção e supressão de psicose, déficit de memórias, distúrbios cognitivos, enxaqueca, neuropatia, distúrbios neuro-inflamatórios (por exemplo, esclerose múltipla, síndrome de Guillain-Barre e as seqüelas inflamatórias de encefalite viral), acidentes vasculares cerebrais, trauma na cabeça, distúrbios de ansiedade, estresse, epilepsia, mal de Parkinson e esquizofrenia. Os compostos são também utilizáveis para o tratamento de distúrbios de abuso de substâncias, particularmente aos opiatos, álcool e nicotina. Os compostos são também utilizáveis no tratamento de obesidade e distúrbios de alimentação associados com a ingestão excessiva de alimentos e complicações associadas com os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53224703P | 2003-12-23 | 2003-12-23 | |
PCT/US2004/039763 WO2005066126A1 (en) | 2003-12-23 | 2004-12-13 | Cb1 modulator compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0418079A true BRPI0418079A (pt) | 2007-04-17 |
Family
ID=34748790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0418079-8A BRPI0418079A (pt) | 2003-12-23 | 2004-12-13 | composto, composição farmacêutica, e, usos de uma composição e de um composto |
Country Status (17)
Country | Link |
---|---|
US (2) | US7276516B2 (pt) |
EP (1) | EP1699761B1 (pt) |
JP (1) | JP2007519631A (pt) |
AR (1) | AR047160A1 (pt) |
AT (1) | ATE502009T1 (pt) |
AU (1) | AU2004312311A1 (pt) |
BR (1) | BRPI0418079A (pt) |
CA (1) | CA2549396A1 (pt) |
DE (1) | DE602004031875D1 (pt) |
ES (1) | ES2360112T3 (pt) |
IL (1) | IL176069A0 (pt) |
NO (1) | NO20063381L (pt) |
PE (1) | PE20050598A1 (pt) |
SV (1) | SV2005001984A (pt) |
TW (1) | TW200522944A (pt) |
WO (1) | WO2005066126A1 (pt) |
ZA (1) | ZA200605159B (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
WO2004056363A2 (en) | 2002-12-20 | 2004-07-08 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
GB0516379D0 (en) * | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
US7544676B2 (en) | 2005-11-10 | 2009-06-09 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
FR2893615B1 (fr) * | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
WO2007098418A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
WO2007138611A1 (en) * | 2006-05-30 | 2007-12-06 | Suven Life Sciences Limited | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands |
US9079854B2 (en) | 2007-07-13 | 2015-07-14 | The Cleveland Clinic Foundation | Hydrazone modulators of cannabinoid receptors |
WO2009012227A1 (en) * | 2007-07-13 | 2009-01-22 | Board Of Regents, The University Of Texas System | Hydrazone modulators of cannabinoid receptors |
US7759335B2 (en) * | 2008-01-31 | 2010-07-20 | Jenrm Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
US20100056491A1 (en) * | 2008-08-29 | 2010-03-04 | Memory Pharmaceuticals Corporation | 4'-amino cyclic compounds having 5-ht6 receptor affinity |
US8318725B2 (en) * | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
KR101712035B1 (ko) * | 2009-06-29 | 2017-03-03 | 아지오스 파마슈티컬스 아이엔씨. | 치료용 화합물 및 조성물 |
US20130045992A1 (en) | 2010-01-28 | 2013-02-21 | President And Fellows Of Harvard College | Compositions and Methods for Enhancing Proteasome Activity |
EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
JP5728099B2 (ja) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体 |
EP2699577A1 (en) | 2011-04-20 | 2014-02-26 | Glaxo Group Limited | Tetrahydropyrazolo [1,5 -a]pyrimidine as anti -tuberculosis compounds |
CA2835610C (en) | 2011-05-12 | 2017-03-14 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
CA2860986A1 (en) * | 2012-01-16 | 2013-07-25 | Bayer Intellectual Property Gmbh | Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
TW201410243A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型1(cb1)媒介之疾病之拉喹莫德(laquinimod) |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
RU2557971C2 (ru) * | 2013-07-31 | 2015-07-27 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ воздействия на функциональную активность каннабиноидного рецептора |
RU2582393C2 (ru) * | 2013-07-31 | 2016-04-27 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения ожирения и сопутствующих метаболических расстройств |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
NZ726874A (en) * | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
JP2017521480A (ja) * | 2014-05-23 | 2017-08-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ベンゼンスルホンアミド誘導体及びrorcモデュレーターとしてのその使用 |
WO2017180948A1 (en) | 2016-04-15 | 2017-10-19 | Ronald Silver | Cannabinoid and caffeine emulsifications |
EP3442522A4 (en) | 2016-04-15 | 2020-01-01 | SRE Wellness, Inc. | PROCESS FOR PRODUCING HYDROPHILIZED CANNABIS OIL USING EMULSIFIERS, AND COMPOSITIONS OF CANNABINOIDS THEREOF |
CN106349196B (zh) * | 2016-08-26 | 2019-01-04 | 江苏克胜作物科技有限公司 | 一种呋虫胺的合成方法 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018210658A1 (en) * | 2017-05-15 | 2018-11-22 | Basf Se | Heteroaryl compounds as agrochemical fungicides |
WO2020118048A1 (en) * | 2018-12-07 | 2020-06-11 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
CN113861194B (zh) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用 |
WO2023235305A2 (en) * | 2022-05-31 | 2023-12-07 | Lysoway Therapeutics, Inc. | Sulfonyl cyclic derivatives, and compositions and methods thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
CA2245586A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
US6100259A (en) | 1997-01-21 | 2000-08-08 | Smithkline Beecham Corporation | Cannabinoid receptor modulators |
RU2203272C2 (ru) | 1997-02-21 | 2003-04-27 | Байер Акциенгезелльшафт | Замещенные бициклические соединения, исходные и промежуточные продукты для их получения и фармацевтическая композиция на их основе |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
WO1999002499A1 (fr) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Composes quinoline et utilisations de ceux-ci en medecine |
HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
WO2000030683A1 (fr) * | 1998-11-19 | 2000-06-02 | Shionogi & C0., Ltd. | Composes prophylactiques et/ou therapeutiques destines a des maladies du systeme nerveux central et possedant des composes antagonistes du recepteur de txa2 et/ou inhibiteurs de la txa2 synthase |
WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
WO2002032863A1 (en) * | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
US20020128208A1 (en) * | 2000-12-15 | 2002-09-12 | Snyder James P. | Nonpeptide agonists and antagonists of vasopressin receptors |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
CN1529595A (zh) | 2001-09-21 | 2004-09-15 | ������ҩ������˾ | 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物 |
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
EP1506960B1 (en) | 2003-08-07 | 2011-04-06 | National Health Research Institutes | Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis-related disorders |
-
2004
- 2004-11-23 TW TW093136000A patent/TW200522944A/zh unknown
- 2004-12-10 PE PE2004001249A patent/PE20050598A1/es not_active Application Discontinuation
- 2004-12-13 WO PCT/US2004/039763 patent/WO2005066126A1/en not_active Application Discontinuation
- 2004-12-13 JP JP2006547015A patent/JP2007519631A/ja active Pending
- 2004-12-13 ES ES04812310T patent/ES2360112T3/es active Active
- 2004-12-13 AT AT04812310T patent/ATE502009T1/de not_active IP Right Cessation
- 2004-12-13 CA CA002549396A patent/CA2549396A1/en not_active Abandoned
- 2004-12-13 EP EP04812310A patent/EP1699761B1/en active Active
- 2004-12-13 US US10/596,495 patent/US7276516B2/en not_active Expired - Fee Related
- 2004-12-13 AU AU2004312311A patent/AU2004312311A1/en not_active Abandoned
- 2004-12-13 DE DE602004031875T patent/DE602004031875D1/de active Active
- 2004-12-13 BR BRPI0418079-8A patent/BRPI0418079A/pt not_active IP Right Cessation
- 2004-12-21 AR ARP040104819A patent/AR047160A1/es unknown
- 2004-12-22 SV SV2004001984A patent/SV2005001984A/es not_active Application Discontinuation
-
2006
- 2006-05-31 IL IL176069A patent/IL176069A0/en unknown
- 2006-06-22 ZA ZA200605159A patent/ZA200605159B/en unknown
- 2006-07-21 NO NO20063381A patent/NO20063381L/no not_active Application Discontinuation
-
2007
- 2007-08-17 US US11/840,417 patent/US7595339B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7595339B2 (en) | 2009-09-29 |
EP1699761B1 (en) | 2011-03-16 |
AR047160A1 (es) | 2006-01-11 |
DE602004031875D1 (de) | 2011-04-28 |
SV2005001984A (es) | 2005-11-04 |
WO2005066126A1 (en) | 2005-07-21 |
ATE502009T1 (de) | 2011-04-15 |
US20080287504A1 (en) | 2008-11-20 |
ZA200605159B (en) | 2007-12-27 |
US7276516B2 (en) | 2007-10-02 |
PE20050598A1 (es) | 2005-08-15 |
ES2360112T3 (es) | 2011-06-01 |
NO20063381L (no) | 2006-09-20 |
JP2007519631A (ja) | 2007-07-19 |
IL176069A0 (en) | 2006-10-05 |
US20070088018A1 (en) | 2007-04-19 |
TW200522944A (en) | 2005-07-16 |
CA2549396A1 (en) | 2005-07-21 |
EP1699761A1 (en) | 2006-09-13 |
AU2004312311A1 (en) | 2005-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0418079A (pt) | composto, composição farmacêutica, e, usos de uma composição e de um composto | |
BR0308349A (pt) | Composto, composição, e, uso de um composto | |
BRPI0411131A (pt) | composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto | |
WO2003007887A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
BR112017018022A2 (pt) | "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
PL1776119T3 (pl) | Pochodne tetrahydro-naftalenu jako modulatory receptora glukokortykoidowego | |
RU2018115569A (ru) | Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах | |
ATE528005T1 (de) | 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen | |
MX2012007410A (es) | Compuestos antivirales novedosos. | |
BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
BRPI0518096A (pt) | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos | |
EA201170240A1 (ru) | Новые замещенные производные сульфамидов | |
BRPI0406827A (pt) | Processo para a modificação da formação de cristal de droga | |
IL159960A (en) | Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments | |
ME01456B (me) | Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola | |
GB0620385D0 (en) | Novel compounds | |
JP2015514781A5 (pt) | ||
CL2008000738A1 (es) | Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda | |
CY1111256T1 (el) | Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους | |
ATE548353T1 (de) | Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon. | |
JP2019536764A5 (pt) | ||
ECSP088477A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |